Pitfalls in the Response Evaluation After Peptide Receptor Radionuclide Therapy With [ 177 Lu-Dota 0 ,Tyr 3 ]Octreotate

Endocrine-Related Cancer - United Kingdom
doi 10.1530/erc-16-0524
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

Peptide Receptor Radionuclide Therapy in Patients With Medullary Thyroid Carcinoma: Predictors and Pitfalls

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Practıcal Aspects of 68Ga-Labelled Dota-Peptides for Peptide-Receptor Radionuclide Therapy

Journal of Engineering Technology and Applied Sciences
2016English

Nephrotoxicity After PRRT With 177Lu-Dota-Octreotate

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2016English

Predictors of Long-Term Outcome in Patients With Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2014English

Peptide Receptor Radionuclide Therapy

Best Practice and Research in Clinical Gastroenterology
Gastroenterology
2005English

Peptide Receptor Radionuclide Therapy

2007English

[ 177 Lu]-Psma-617 Radionuclide Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

New Developments in Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Reply: Peptide Receptor Radionuclide Therapy in the United States

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy